InflaRx Stock (NASDAQ:IFRX), Trade Ideas

InflaRx

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

APTO

AREB

CISS

CVKD

IFRX

Intelligent Bio Solutions Inc. - Common Stock

INBS

INTC

JAGX

KLAC

ONCO

REVB

TCBP

TELL

VMAR

WLGS

YIBO

Shares of  Tellurian Inc. (NASDAQ: TELL) shares rose sharply in pre-market trading following a report suggesting the company hired Lazard to explore a possible sale.

Tellurian shares jumped 16.3% to $0.6050 in pre-market trading

Why Tellurian Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

AAPL

ARBB

BDRX

BILL

CYTO

DMTK

DOCN

EIGR

EZGO

FOXF

FTNT

HIPO

INSG

INVO

MCAF

NVOS

RVSN

SECO

Gainers

Altamira Therapeutics Ltd (NASDAQ: CYTO) shares surged 54.1% to $0.25 in pre-market trading after gaining 5% on Thursday.

Why DigitalOcean Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

AMTD

APRN

AUUD

CYXT

DATS

FRZA

IFBD

KDNY

MCOM

MDGS

Airspan Networks Holdings Inc. Common Stock

MIMO

ONCR

SIEN

TENX

Gainers


	Auddia Inc.  (NASDAQ: AUUD) shares rose 103.2% to $0.8809 in pre-market trading after gaining around 9% on Friday.


Why Oncorus Shares Are Trading Lower By 25%; Here Are 20 Stocks Moving Premarket

InflaRx NV

DA Davidson analyst Jeffrey Rulis maintains Enterprise Finl Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSC#NASDAQ">EFSC</a>) with a Buy and lowers the price target from $47 to $45.

Price Target

Analyst Ratings

EFSC

DA Davidson Maintains Buy on Enterprise Finl Servs, Lowers Price Target to $45

Compass Point analyst Casey Alexander maintains RLI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLI#NYSE">RLI</a>) with a Buy and raises the price target from $158 to $175.

Compass Point Maintains Buy on RLI, Raises Price Target to $175

General Motors Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) exceeded earnings expectations as it reported first-quarter (<a href="https://www.benzinga.com/quote/GM/earnings">Q1) earnings on Tuesday</a>. 
The company achieved a 7.6% year-on-year increase in quarterly sales, reaching $43.01 billion, surpassing the analyst consensus of $41.88 billion. Additionally, adjusted EPS stood at $2.62, outperforming the consensus estimate of $2.14. 
Despite these gains, GM&#8217;s market share dipped slightly to 8.1% overall, with decreases noted in both the U.S. and China compared to the previous year. The stock closed lower on Tuesday but has been trading in the green on Wednesday.
Here&#8217;s what analysts have said about GM&#8217;s first-quarter (Q1) earnings report:
<ul>
<li>Goldman Sachs analyst Mark Delaney, CFA has a Buy rating on GM stock with a 12-month price target of $52. The price target implies an upside of 15.3%.</li>
<li>Piper Sandler analyst Alexander Potter has Neutral rating on the stock with a price target of $45 a share.</li>
<li>BofA Securities analyst John Murphy, CFA has a Buy rating on the stock with a price objective of $75 &#8211; implying an upside of 66.3%.</li>
<li>Mizuho Securities analyst Vijay Rakesh maintained Buy rating on the stock while raising price target from $48 to $52.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36389849/evs-outrank-ai-among-top-revenue-drivers-for-semiconductor-industry-in-2024-survey">EVs Outrank AI Among Top Revenue Drivers For Semiconductor Industry In 2024: Survey</a>
Goldman Sachs: Delaney highlighted GM&#8217;s robust margins and free cash flow, alongside progress in electric vehicles (EVs) and overall profitability. &#8220;Margins can remain resilient, driven both by cost/efficiencies and relatively firm pricing,&#8221; he said.
Delaney views EV profitability progress positively, noting relative demand strength for GM&#8217;s EVs. He anticipates investor focus on GM&#8217;s ability to achieve profitability targets in EVs, particularly in 2025.
&#8220;We believe capital allocation will remain a tailwind,&#8221; Delaney noted.
Piper Sandler: Despite GM&#8217;s impressive quarter and a 5% post-earnings stock surge, there&#8217;s caution due to potential margin decline in the second half of 2024 from rising EV sales. 
Potter notes &#8220;highly uncertain implications of rising EV sales in 2H24 and beyond&#8221;, impacting extrapolation from strong Q1 results. Nevertheless, upward estimate revisions and increased buybacks support a higher price target of $45, up from $44.
BofA Securities: According to Murphy, GM remains focused on and &#8220;is continuing to make meaningful investments in the Core-to-Future transition.&#8221; Its strong execution in the Core business should enable investments in EVs and AVs. 
Continued development in mobility services may unlock value over time. GM focuses on growing its EV business profitably, aiming for breakeven in the second half of 2024 and 200k+ EV volumes by 2024. The company remains committed to Cruise and will provide further updates at the upcoming Investor Day.
Mizuho Securities: Rakesh sees &#8220;GM well positioned with its ICE leadership position in the SUV/pick-up truck markets, and more disciplined EV rollout plan.&#8221; 
The company&#8217;s premium vehicle lineup, including full-size pickups and SUVs, maintained dominance in the US market, with full-size SUV market share increasing by 300 basis points to 66%. EV sales surged by 74% quarter-on-quarter, driven by Ultium-based models like the Cadillac LYRIQ and Chevy Silverado EV work truck, aligning with the company&#8217;s expectation of significant production growth in 2024.
Read Next: <a href="https://www.benzinga.com/news/24/04/38400974/tesla-to-180-here-are-10-top-analyst-forecasts-for-wednesday">Tesla To $180? Here Are 10 Top Analyst Forecasts For Wednesday</a>

Analyst Color

Earnings

Long Ideas

4 General Motors Analysts Confirm Strong EV Strategy: 'Capital Allocation Will Remain A Tailwind'

Needham analyst Mike Matson maintains OncoCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCX#NASDAQ">OCX</a>) with a Buy and raises the price target from $3.6 to $4.25.

Needham Maintains Buy on OncoCyte, Raises Price Target to $4.25

Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>) has generated significant gains over the past seven days, prompting analysts to foresee further <a href="https://www.benzinga.com/money/pepe-price-prediction">bullish price action</a>.
What Happened: Meme coin analyst and trader Murad highlights how Pepe, a &#8220;cult community with more than 10 million unique memes,&#8221; could flip Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) and Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>):
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I think it is possible that <a href="https://twitter.com/search?q=%24PEPE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$PEPE</a> flips <a href="https://twitter.com/search?q=%24SHIB&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SHIB</a> and possibly even <a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a>.<a href="https://twitter.com/search?q=%24PEPE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$PEPE</a> is a cult community with 10,000,000+ unique memes that is perpetually relevant to modern culture, while <a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> is literally just a single pic and <a href="https://twitter.com/search?q=%24SHIB&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SHIB</a> has zero memes to speak of.
&mdash; Murad (@MustStopMurad) <a href="https://twitter.com/MustStopMurad/status/1782776856548085850?ref_src=twsrc%5Etfw">April 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
He calls the meme coin &#8220;perpetually relevant to modern culture, while DOGE is just a single pic and SHIB has zero memes to speak of.&#8221; 
While the crypto community had different reactions to the tweet, some suggested other meme coins like Floki (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">FLOKI</a>) that could flip the meme coin leaders instead of Pepe.
One crypto trader <a href="https://twitter.com/blockchaingod69/status/1782874083807682693">stated</a> that &#8220;Doge is an OG classic and the first-ever meme coin,&#8221; and that PEPE could flip every other meme coin except for Dogecoin. 
Price Action: At the time of writing, PEPE was trading at $ 0.000007491, down 3.3% over the past 24 hours but up 50% over the past seven days.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/24/04/38396592/dogecoin-millionaire-reacts-to-strategy-involving-heavy-allocation-to-pepe-dogewifhat-basically-my-e">Dogecoin &#8216;Millionaire&#8217; Reacts To Strategy Involving Heavy Allocation To Pepe, Dogewifhat: &#8216;Basically My Entire Plan&#8217;</a>
Why It Matters: Hedge fund manager Thomas Kralow, in his latest tweet, highlighted how a whale has accumulated 211.6 billion PEPE tokens, worth $1.72 million, over the past day. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f575;&#xfe0f;&#x200d;&#x2642;&#xfe0f; Whale has amassed 211.6 billion <a href="https://twitter.com/search?q=%24PEPE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$PEPE</a> (~$1.72M) over the past day, driving the price up by 17%. His most recent withdrawal from the <a href="https://twitter.com/hashtag/exchange?src=hash&amp;ref_src=twsrc%5Etfw">#exchange</a> was just 2 hours ago. <a href="https://t.co/hY0tSOpywU">pic.twitter.com/hY0tSOpywU</a>
&mdash; Thomas Kralow (@TKralow) <a href="https://twitter.com/TKralow/status/1783136831107727828?ref_src=twsrc%5Etfw">April 24, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
IntoTheBlock data shows an increase in transactions greater than 100,000, with 78% of Pepe holders currently making a profit and a concentration of 73% by large holders. The meme coin&#8217;s price correlation with Bitcoin stands at 0.83, and amongst all meme coins, Pepe reported the largest increase in holders&#8217; balance at 1.34%, reaching $225.8 million.
What's Next: The influence of meme coins and&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;are topics expected to be thoroughly explored at Benzinga's upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38365707/pepe-coin-skyrockets-17-traders-note-very-bullish-technical-setup">Pepe Coin Skyrockets 17%, Traders Note &#8216;Very Bullish&#8217; Technical Setup</a>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$FLOKI

$PEPE

$SHIB

Pepe Up 50% On The Week: 'Cult Community' May 'Flip SHIB And Possibly Even DOGE,' Predicts Influential Trader

KeyBanc&nbsp;analyst Thomas Blakey initiated coverage on&nbsp;Super Micro Computer Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) with a&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/SMCI/analyst-ratings" rel="noreferrer noopener">Sector Weight rating</a>.
SMCI shares are trading relatively in line with its infrastructure peer group at 27x calendar 2024 P/E vs. peers&#8217; 28x average. The 27x for SMCI compares to 17x for low gross margin peers, but he noted Super Micro&#8217;s faster growth warrants near-term premium.&nbsp;
Super Micro, a leading ODM/OEM of IT infrastructure (compute, storage, networking, liquid cooling), is well positioned to benefit from secular AI growth trends provided its ability to deliver highly customized complete IT solutions leveraging its in-house engineering design expertise based on the latest technology (i.e., GPUs) in the fastest, most efficient manner, Blakey noted.
The opportunity set may extend as AI becomes more pervasive over time, driving the theme of accelerated computing where relative bespoke GPU-based solutions and other and non-x86 (i.e.,&nbsp;Arm Holdings Plc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arm#NASDAQ">ARM</a>)) solutions take share in what the CEO of&nbsp;Nvidia Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) has recently described as a $1 trillion installed base opportunity currently based chiefly on x86 CPUs and ASICs.
Blakey estimates that Super Micro will reach an approximately 23% share of the AI server market in calendar 2024, with competitive moats that should sustain, if not expand, this share in coming years.
The analyst noted that checks indicate other OEMs are making inroads&nbsp;and again&nbsp;highlights&nbsp;this market could expand beyond current forecasts provided AI-driven demands lead to more GPU-based compute supplanting CPUs.
From a pricing perspective, Blakey&#8217;s checks indicate demand continues to outpace supply for core GPUs and power, which should keep component prices high for the foreseeable future and drive Super Micro&#8217;s model.&nbsp;
As power becomes more accessible, he noted rack-scale solution configurations could also move higher (i.e., more GPUs), leading to more upward pressure. He said liquid cooling would also add a pricing uplift to rack-scale solutions as Super Micro and others add this vital feature to reduce energy costs in data centers.
From a unit perspective, Super Micro currently can ship 5,000 rack-scale complete IT solutions today per month, and Blakey&nbsp;estimates the company is presently running at ~60% capacity utilization, which compares to 2,000 racks per month in calendar 2022 and the possibility of doubling capacity from current 5k per month by expanding to Malaysia, Mexico, and Texas.
Blakey noted Super Micro&#8217;s predominant North American-based manufacturing today&nbsp;is often viewed&nbsp;as a competitive advantage in addition to the company&#8217;s engineering and design expertise.
In the most recent quarter, Super Micro grew topline 103% vs. 54% a year ago and posted a gross margin of 15.5% vs. 18.8% and an operating margin of 11.3% vs. 12.8%, respectively.&nbsp;Blakey noted that Super Micro is competitively priced in the market; hence, expect gross margin to remain in the 15% range if not experience modest pressure with the company focusing more on&nbsp;EBIT leverage long-term.&nbsp;
In the most recent quarter, Super Micro had customer concentration with two customers amounting to 37% and four customers accounting for 67% of accounts receivable, Blakey said. Customers of Super Micro include AI-infrastructure leaders such as CoreWeave, Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), X, and Nutanix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>), he added.
Blakey projected third-quarter revenue and EPS of $3.99 billion and $5.83.
Wedbush&nbsp;analyst Matt Bryson reiterated Super Micro Computer with a Neutral and a $530&nbsp;price target.
Super Micro reports after the close, April 30. Bryson noted the most likely outcome as a modest beat followed by a guide that is at least in line, if not better than prior expectations.
His conversations with the supply chain and other OEMs suggest strong demand for AI servers through the calendar first and second quarters, supported by lifting OEM/ODM component orders.
Bryson noted that GPU shortages&nbsp;appear to&nbsp;have dissipated significantly, limiting the likelihood of supply chain issues disrupting/limiting OEM server sales.
At the same time, his conversations with SMCI competitors throughout the calendar first quarter suggested that the backlog built in 2023 and early 2024 provided visibility to OEM server vendors, at least through the calendar second quarter.&nbsp;
Bryson projected third-quarter revenue and EPS of $3.90 billion and $5.63.
Price Action: SMCI shares traded lower by 0.84% at $756.00 at the last check Wednesday.
Photo via Midjourney

Equities

Initiation

Reiteration

NTNX

NVDA

SMCI

TSLA

AI Server Market Is Expanding Rapidly - Analysts Highlight Super Micro Computer's Importance In The Game

HC Wainwright &amp; Co. analyst Ed Arce maintains Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) with a Buy and raises the price target from $17 to $19.

TVTX

HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $19

WIIM

Trump Media shares are trading higher after the company's CEO reportedly sent a letter urging House GOP leaders to investigate possible manipulation of the stock.

Canaccord Genuity analyst Dalton Baretto maintains Silvercorp Metals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SVM#TSX">SVM</a>) with a Buy and lowers the price target from C$7.5 to C$7.

TSX:SVM

Canaccord Genuity Maintains Buy on Silvercorp Metals, Lowers Price Target to C$7

JMP Securities reiterates Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Market Outperform and maintains $225 price target.

AMZN

JMP Securities Reiterates Market Outperform on Amazon.com, Maintains $225 Price Target

U.S. stocks traded slightly lower toward the end of trading, with the S&amp;P 500 edging lower on Wednesday.
The Dow traded down 0.18% to 38,434.99 while the NASDAQ fell 0.09% to 15,682.38. The S&amp;P 500 also fell, dropping, 0.14% to 5,063.45.
Check This Out: <a href="https://www.benzinga.com/news/24/04/38400974/tesla-to-180-here-are-10-top-analyst-forecasts-for-wednesday">Tesla To $180? Here Are 10 Top Analyst Forecasts For Wednesday</a>
Leading and Lagging Sectors Consumer staples shares climbed by 0.8% on Wednesday.
In trading on Wednesday, industrials shares fell by 0.9%.
Top Headline
AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) reported fiscal first-quarter 2024 operating revenues of $30.03 billion, down 0.4% year over year and missing the consensus of $30.54 billion. Adjusted EPS of 55 cents beat the consensus of 54 cents.
AT&amp;T reiterated Wireless service revenue growth in the 3% range, Broadband revenue growth of 7%+, and adjusted EPS of $2.15 – $2.25 versus the $2.21 consensus.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>BranchOut Food Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>) shares shot up 61% to $1.83 after the company announced it has expanded its existing relationship with the nation&#8217;s largest retailer, which brings the total annualized value of commitments from the retailer to over $8 million.</li>
<li>Shares of Amesite Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMST#NASDAQ">AMST</a>) got a boost, surging 61% to $3.2050 after the company announced the Beta release of its NurseMagic app.</li>
<li>B. Riley Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) shares were also up, gaining 44% to $31.25 after the company announced the results of an independent investigation showed the company and its executives had no involvement with, or knowledge of, any of the alleged misconduct concerning Mr. Kahn or any of his affiliates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) shares dropped 33% to $5.23. The company reported FY23 financial results. Evotec announced a priority reset to optimize its business to meet evolving market demand and focus on profitable growth in 2024 and beyond.</li>
<li>Shares of Avenue Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) were down 31% to $0.0924 after the company announced a reverse stock split.</li>
<li>iSun, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISUN#NASDAQ">ISUN</a>) was down, falling 41% to $0.09 after the company announced a reverse stock split.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38399483/alzamend-neuro-and-2-other-stocks-under-5-insiders-are-buying">Alzamend Neuro And 2 Other Stocks Under $5 Insiders Are Buying</a>
Commodities In commodity news, oil traded down 0.9% to $82.59 while gold traded down 0.3% at $2,336.10.
Silver traded down 0.4% to $27.265 on Wednesday, while copper rose 0.6% to $4.4595.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.43%, London's FTSE 100 fell 0.06% while Spain's IBEX 35 Index fell 0.43% The German DAX fell 0.27% French CAC 40 fell 0.17% while Italy's FTSE MIB Index fell 0.27%.
The Ifo Business Climate indicator for Germany climbed to 89.4 in April, topping market estimates of 88.9.
Asia Pacific Markets
Asian markets closed mostly higher on Tuesday, with Japan's Nikkei 225 gaining 2.42%, Hong Kong's Hang Seng Index gaining 2.21%, China's Shanghai Composite climbing 0.76% and India's S&amp;P BSE Sensex gaining 0.16%.
Australia&#8217;s inflation rate fell to 3.6% year-over-year in the first quarter from 4.1% in the previous period.
Economics
<ul>
<li>U.S. mortgage applications declined by 2.7% from the prior week in the period ending April 19.</li>
<li>New orders for manufactured durable goods rose by 2.6% month-over-month in March compared to a revised 0.7% gain in February.</li>
<li>The EIA said crude oil inventories in the U.S. declined by 6.368 million barrels in the week ended April 19, versus market estimates of a 1.6 million gain.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/04/38400430/top-3-energy-stocks-that-may-crash-this-quarter">Top 3 Energy Stocks That May Crash This Quarter</a>

Eurozone

Commodities

Intraday Update

AMST

ATXI

ISUN

RILY

Crude Oil Moves Lower; B. Riley Financial Shares Jump

Deep-pocketed investors have adopted a bullish approach towards Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in BAC usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 35 extraordinary options activities for Bank of America. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 54% leaning bullish and 42% bearish. Among these notable options, 14 are puts, totaling $1,102,213, and 21 are calls, amounting to $1,127,054.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $40.0 for Bank of America during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Bank of America's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Bank of America's substantial trades, within a strike price spectrum from $20.0 to $40.0 over the preceding 30 days.
<h3>Bank of America 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713983550_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$2.03</td>
<td>$2.01</td>
<td>$2.02</td>
<td>$37.00</td>
<td>$424.4K</td>
<td>2.7K</td>
<td>0</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$7.55</td>
<td>$7.45</td>
<td>$7.55</td>
<td>$31.00</td>
<td>$242.2K</td>
<td>3.1K</td>
<td>322</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$9.5</td>
<td>$9.4</td>
<td>$9.4</td>
<td>$29.00</td>
<td>$127.8K</td>
<td>193</td>
<td>136</td>
</tr>
<tr>
<td>BAC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1.78</td>
<td>$1.48</td>
<td>$1.5</td>
<td>$32.00</td>
<td>$93.7K</td>
<td>5.9K</td>
<td>1.2K</td>
</tr>
<tr>
<td>BAC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.51</td>
<td>$1.48</td>
<td>$1.5</td>
<td>$32.00</td>
<td>$93.7K</td>
<td>5.9K</td>
<td>626</td>
</tr>
</tbody>
</table>

<h3>About Bank of America</h3>
Bank of America is one of the largest financial institutions in the United States, with more than $3.0 trillion in assets. It is organized into four major segments: consumer banking, global wealth and investment management, global banking, and global markets. Bank of America's consumer-facing lines of business include its network of branches and deposit-gathering operations, retail lending products, credit and debit cards, and small-business services. The company's Merrill Lynch operations provide brokerage and wealth-management services, as does its private bank. Wholesale lines of business include investment banking, corporate and commercial real estate lending, and capital markets operations. Bank of America has operations in several countries but is primarily US-focused.
Following our analysis of the options activities associated with Bank of America, we pivot to a closer look at the company's own performance.
<h3>Where Is Bank of America Standing Right Now?</h3>
<ul>
<li>With a trading volume of 16,643,380, the price of BAC is down by -0.81%, reaching $38.06.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 83 days from now.</li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Bank of America options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Spotlight on Bank of America: Analyzing the Surge in Options Activity

Whales with a lot of money to spend have taken a noticeably bearish stance on Applied Mat.
Looking at options history for Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) we detected 12 trades.
If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish expectations and 75% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $184,862 and 8, calls, for a total amount of $453,391.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $140.0 to $225.0 for Applied Mat over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Applied Mat's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Applied Mat's significant trades, within a strike price range of $140.0 to $225.0, over the past month.
<h3>Applied Mat Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713983545_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$13.95</td>
<td>$13.85</td>
<td>$13.85</td>
<td>$195.00</td>
<td>$99.7K</td>
<td>920</td>
<td style="text-align: right;">236</td>
</tr>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$16.5</td>
<td>$16.4</td>
<td>$16.4</td>
<td>$195.00</td>
<td>$85.2K</td>
<td>246</td>
<td style="text-align: right;">106</td>
</tr>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$44.8</td>
<td>$44.75</td>
<td>$44.8</td>
<td>$165.00</td>
<td>$62.7K</td>
<td>1.2K</td>
<td style="text-align: right;">9</td>
</tr>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$11.6</td>
<td>$11.55</td>
<td>$11.55</td>
<td>$195.00</td>
<td>$60.0K</td>
<td>663</td>
<td style="text-align: right;">90</td>
</tr>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$11.55</td>
<td>$11.55</td>
<td>$11.55</td>
<td>$190.00</td>
<td>$57.7K</td>
<td>1.2K</td>
<td style="text-align: right;">92</td>
</tr>
</tbody>
</table>

<h3>About Applied Mat</h3>
Applied Materials is the largest semiconductor wafer fabrication equipment, or WFE, manufacturer in the world. Applied Materials has a broad portfolio spanning nearly every corner of the WFE ecosystem. Specifically, Applied Materials holds a market share leadership position in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.
Following our analysis of the options activities associated with Applied Mat, we pivot to a closer look at the company's own performance.
<h3>Where Is Applied Mat Standing Right Now?</h3>
<ul>
<li>With a volume of 2,337,457, the price of AMAT is up 2.46% at $198.0. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 22 days.</li>
</ul>
<h3>What The Experts Say On Applied Mat</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $260.0.
<ul>
<li>An analyst from Cantor Fitzgerald has elevated its stance to Overweight, setting a new price target at $260. </li>
<li>An analyst from Evercore ISI Group has revised its rating downward to Outperform, adjusting the price target to $260. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Applied Mat options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

AMAT

Applied Mat Options Trading: A Deep Dive into Market Sentiment

High-rolling investors have positioned themselves bullish on Futu Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in FUTU often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 17 options trades for Futu Hldgs. This is not a typical pattern.
The sentiment among these major traders is split, with 76% bullish and 23% bearish. Among all the options we identified, there was one put, amounting to $63,910, and 16 calls, totaling $1,639,512.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $50.0 to $95.0 for Futu Hldgs over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Futu Hldgs stands at 1230.91, with a total volume reaching 3,414.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Futu Hldgs, situated within the strike price corridor from $50.0 to $95.0, throughout the last 30 days.
<h3>Futu Hldgs Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713983539_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FUTU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/26/24</td>
<td>$11.4</td>
<td>$9.95</td>
<td>$11.0</td>
<td>$54.00</td>
<td>$440.0K</td>
<td>1.6K</td>
<td style="text-align: right;">490</td>
</tr>
<tr>
<td>FUTU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/26/24</td>
<td>$12.45</td>
<td>$11.0</td>
<td>$11.0</td>
<td>$54.00</td>
<td>$289.3K</td>
<td>1.6K</td>
<td style="text-align: right;">127</td>
</tr>
<tr>
<td>FUTU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$15.7</td>
<td>$15.2</td>
<td>$15.7</td>
<td>$50.00</td>
<td>$149.1K</td>
<td>4.2K</td>
<td style="text-align: right;">316</td>
</tr>
<tr>
<td>FUTU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/26/24</td>
<td>$12.35</td>
<td>$11.0</td>
<td>$11.0</td>
<td>$54.00</td>
<td>$111.1K</td>
<td>1.6K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>FUTU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/26/24</td>
<td>$12.9</td>
<td>$11.0</td>
<td>$11.0</td>
<td>$54.00</td>
<td>$110.0K</td>
<td>1.6K</td>
<td style="text-align: right;">390</td>
</tr>
</tbody>
</table>

<h3>About Futu Hldgs</h3>
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Following our analysis of the options activities associated with Futu Hldgs, we pivot to a closer look at the company's own performance.
<h3>Where Is Futu Hldgs Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 2,410,645, with FUTU's price up by 1.71%, positioned at $62.99.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 28 days.</li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Futu Hldgs, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

FUTU

What the Options Market Tells Us About Futu Hldgs

Citigroup analyst Roland Shu upgrades United Microelectronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMC#NYSE">UMC</a>) from Neutral to Buy.

Upgrades

Citigroup Upgrades United Microelectronics to Buy

A recent&nbsp;academic case study, published on April 22, examined&nbsp;using&nbsp;Amgen Inc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Blincyto, a bispecific CD3xCD19 T-cell engager, to treat a patient with severe systemic sclerosis.&nbsp;
The findings have implications for&nbsp;Cullinan Therapeutics Inc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>) CLN-978, a similar CD19xCD3 bispecific T-cell engager.
Most recently, Cullinan Therapeutics, formerly&nbsp;Cullinan Oncology, announced its plans to expand into autoimmune diseases and intends to pursue the development of CLN-978 in autoimmune diseases, with systemic lupus erythematosus&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38277370/cullinan-shifts-focus-from-oncology-to-autoimmune-disorders-raises-280m-via-equity" rel="noreferrer noopener">(SLE) as a first indication</a>.&nbsp;
William Blair&nbsp;notes that the case report demonstrates that Blincyto effectively treated a patient with severe systemic sclerosis, leading to rapid B-cell depletion and symptom improvement without increasing infection risk or affecting antibody levels.
This&nbsp;suggests the potential for using B-cell-depleting therapy in autoimmune diseases like systemic lupus erythematosus (SLE),&nbsp;offering easier administration&nbsp;than CAR-T therapy.&nbsp;
CLN-978&#8217;s development will initially target SLE, with Phase 1 submission planned for the third quarter.
William Blair rates&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/CGEM/analyst-ratings" rel="noreferrer noopener">Cullinan shares Outperform</a>&nbsp;based on the significant potential of CLN-619 for endometrial and cervical cancer,&nbsp;zipalertinib&nbsp;for exon 20 mutant lung cancer, CLN-049 for leukemia, and CLN-978 for autoimmune diseases.&nbsp;
They believe the fair value of each share is $33.
Updated data for CLN-619, expected in the second quarter of 2024, will be a&nbsp;key&nbsp;catalyst for the company, along with updates for CLN-978 in lupus and other autoimmune indications.&nbsp;
The development of Cullinan&#8217;s other early-stage oncology assets would provide additional upside.
Earlier Wednesday, Cullinan Therapeutics announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid tumors will&nbsp;be presented&nbsp;at the 2024 American&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38405740/cullinan-therapeutics-to-present-clinical-data-from-phase-1-study-evaluating-novel-anti-micab-anti" rel="noreferrer noopener">Society of Clinical Oncology</a>.
The data will include the first results from the dose escalation cohort of CLN-619 in combination with checkpoint inhibitor pembrolizumab and updated results from the monotherapy dose-escalation cohort in patients with advanced solid tumors.
Price Action: CGEM shares are up 15.10% at $19.18 at the last check Wednesday.
Photo via PublicDomainPictures from Pixabay

Biotech

Health Care

General

AMGN

CGEM

Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?

HSBC analyst Michael Tyndall maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Reduce and lowers the price target from $138 to $120.

HSBC Maintains Reduce on Tesla, Lowers Price Target to $120

Streaming giant Netflix Inc (NASDQ: NFLX) is upping its sports game in 2024 with several news items and the premiere of a comedy roast of Tom Brady, one of the greatest<a href="https://www.benzinga.com/news/23/02/30666186/quarterback-tom-brady-the-goat-announces-nfl-retirement-at-age-44"> NFL players of all time.</a>
What Happened: For years, Netflix had a strategy of <a href="https://www.benzinga.com/general/entertainment/23/12/36222143/netflix-lands-more-live-sports-how-success-of-docuseries-helped-pave-the-way">launching sports-adjacent content,</a> which includes docuseries on sports like Formula 1, tennis, golf and the Tour de France.
With a push into football content, which included the 2023 series "Quarterback," Netflix is now ready to add another direction for sports content.
The streaming company will air a live comedy roast of Tom Brady, titled "The Greatest Roast of All Time: Tom Brady."
An acronym of GROAT for the roast is a play on GOAT, an acronym which means "Greatest of All Time," and is often used to describe legends like Brady.
This marks the first live roast for Netflix and comes as the company has expanded its live content with several live sports specials and a live comedy special featuring Chris Rock.
The roast will be part of the "Netflix Is a Joke Fest" and air on May 5 at 8 p.m. ET, exclusively on Netflix.
Comedian Kevin Hart serves as the host of the roast, with comedian and well-known roaster Jeff Ross also serving as a roaster of Brady. No other guests have been confirmed for the event, with a trailer saying there will be a lineup of surprise guests. Roasters could include athletes, comedians and celebrities.
"No Helmets. No Mercy. No Brady Rule," the trailer reads.
Brady says "I'm unroastable" in the trailer.
Related Link: <a href="https://www.benzinga.com/news/earnings/24/04/38324337/netflix-q1-earnings-highlights-revenue-beat-eps-beat-9-33-million-paid-subs-added-ad-tier-plan-upda">Netflix Q1 Earnings Highlights: Revenue Beat, EPS Beat, 9.33 Million Paid Subs Added, Ad-Tier Plan Update And More</a>
Why It's Important: Brady retired after the 2023 season, which came after returning to the league from a previous retirement decision.
The NFL quarterback retired as the record holder in passing yards, passing touchdowns, NFL Playoff passing yards, NFL Playoff touchdowns and many other records. The winningest NFL quarterback won seven Super Bowls in 10 Super Bowl appearances and won a record five Super Bowl MVP awards.
The roast of Brady marks another move into sports and live content by Netflix, which comes after "The Netflix Slam" aired in March 2024 featuring tennis stars Rafael Nadal and Carlos Alcaraz.
Netflix has also aired a live golf special with golfers and race car drivers.
The company launches perhaps its biggest sporting event ever with a <a href="https://www.benzinga.com/general/entertainment/24/03/37540711/jake-paul-vs-mike-tyson-coming-to-netflix-biggest-fight-in-history">live boxing special </a>featuring Mike Tyson and Jake Paul on July 20.
Netflix also recently <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38146011/wwe-could-be-a-netflix-game-changer-capitalizing-on-opportunities-to-maximize-fan-g">signed a deal</a> with World Wrestling Entertainment, which is a unit of TKO Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>), that will boost its sports content library.
"Receiver," which is a spinoff of "Quarterback" will air on Netflix in summer 2024 and feature NFL players Davante Adams (Las Vegas Raiders), Justin Jefferson (Minnesota Vikings), George Kittle (San Francisco 49ers), Deebo Samuel (San Francisco 49ers) and Amon-Ra St. Brown (Detroit Lions).
Netflix has aired several sports documentaries. It also bid on the media rights to several sports leagues, but has been less aggressive in bidding on sports rights in recent months, saying it wanted to focus on sports-adjacent programming such as docuseries and potentially one-off live events.
&#8220;We aren&#8217;t anti-sports, we&#8217;re pro-profit,&#8221; Netflix co-CEO Ted Sarandos said in January 2023 <a href="https://www.benzinga.com/general/entertainment/23/07/33308114/netflix-doesnt-want-to-live-sports-and-chill-were-happy-with-sports-adjacent-programming-ce">when asked about sports rights.</a>
While the company hasn't won any rights for live matches of the four major North American sports leagues, Netflix continues to push deeper into the world of sports content.
 NFLX Price Action: Netflix shares are down 3.63% to $556.55 on Wednesday versus a 52-week trading range of $315.62 to $639.
Read Next: <a href="https://www.benzinga.com/news/23/08/33552415/from-football-to-futbol-tom-brady-buys-stake-in-this-team-joining-list-of-celebrities-athletes-with">From Football To Futbol: Tom Brady Buys Stake In This Team, Joining List Of Celebrities, Athletes With Pro Sports Ownership</a>
Photos: Brady, Shutterstock; Netflix, Unsplash

Entertainment

Sports

NFLX

Tom Brady To Be Roasted In Live Netflix Special: NFL GOAT Becomes GROAT In Streaming Giant's Continuing Bet On Sports Content

Self-storage center real estate investment trusts (REITs) are companies that specialize in owning and operating income-generating storage facilities, commonly known as self-storage centers. Self-store center REITs invest in properties where individuals and businesses can rent space to store their belongings, such as furniture, household items, business inventory, and vehicles of all types.
Investors in self-storage center REITs benefit from the income generated through leasing storage units to tenants. The demand for self-storage has been driven by various factors, including residential moves, downsizing, and businesses seeking additional space.
If you're interested in investing in a self-storage REIT, here are two you could buy today.
<h2 class="wp-block-heading">Don't Miss:</h2>
<ul>
<li>Investing in real estate just got a whole lot simpler. This <a href="https://www.benzinga.com/go/bezos-landlord">Jeff Bezos-backed startup will allow you to become a landlord</a> in just 10 minutes, and you only need $100.</li>
<li>Want To Grow Your Wealth Passively? Unlock Real Wealth with <a href="https://www.benzinga.com/money/cityfunds-yield">Cityfunds&#8217; Exclusive 8% Yield Fund</a>.</li>
</ul>
<h2 class="wp-block-heading">CubeSmart</h2>
CubeSmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBE#NYSE">CUBE</a>) is the third largest owner and operator of self-storage facilities in the United States with a portfolio of <a href="https://s201.q4cdn.com/604002580/files/doc_presentations/2024/Mar/04/cube-ir-presentation-march-2024-final.pdf">1,406 properties</a> across 178 markets in 41 states and the District of Columbia.
CubeSmart currently pays a quarterly dividend of $0.51 per share, equating to an annualized dividend of $2.04 per share, which gives its stock a yield of about 4.9% at the time of this writing.
In addition to sporting a high yield, CubeSmart is a dividend-growth superstar. Its <a href="https://investors.cubesmart.com/news--events/news-details/2023/CubeSmart-Announces-4.1-Increase-in-Quarterly-Common-Dividend/default.aspx">4.1% hike in December</a> marked the 14th consecutive year in which it has raised its annual dividend payment.
<h2 class="wp-block-heading">Trending:</h2>
<ul>
<li>Want to Create a Passive Income Stream? <a href="https://www.benzinga.com/go/grow-wealth-passively">These High-Yield Real Estate Notes Might Be Your Holy Grail</a></li>
</ul>
<h2 class="wp-block-heading">National Storage Affiliates Trust</h2>
National Storage Affiliates Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSA#NYSE">NSA</a>) is a leading owner and operator of self-storage facilities in the U.S. with ownership interests in <a href="https://d1io3yog0oux5.cloudfront.net/_7cb5f849447bdcf18d510090a08d741e/nationalstorageaffiliates/db/226/5086/pdf/NSA+Presentation_March+Update+2024_FINAL.pdf">1,050 properties</a> containing approximately 68.6 million rentable square feet across 42 states and Puerto Rico.
National Storage currently pays a quarterly dividend of $0.56 per share, equating to an annualized dividend of $2.24 per share, which gives its stock a yield of about 6.3% at the time of this writing.&nbsp;
Like CubeSmart, National Storage is a dividend-growth superstar. It has raised its annual dividend payment every year since its initial public offering in 2015, putting it on track for 2024 to mark the ninth consecutive year with an increase.
<h2 class="wp-block-heading">Read Next:</h2>
<ul>
<li>Elon Musk Is Bullish On Austin. Here&#8217;s <a href="https://www.benzinga.com/go/musk-austin">How To Invest In The City&#8217;s Growth Before He Floods It With New Tech Workers</a>.</li>
<li>Whole Foods&#8217; Landlord Has Achieved A 15% Net IRR For Accredited Investors Since 2015 — <a href="https://www.benzinga.com/go/whole-foods-landlord">Discover The Latest Investment Opportunities On Its Platform</a>.</li>
</ul>
Image Credit: Shutterstock

REIT

Real Estate

CUBE

These Self-Storage REITs Yield Up to 6.3% and Have Track Records of Dividend Growth

Nine months after the U.S. launch of&nbsp;Eisai Limited&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/ESALY#OTC">ESALY</a>) and&nbsp;Biogen Inc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) Leqembi, the first drug shown to slow Alzheimer&#8217;s progression, adoption faces hurdles due to skepticism among some doctors.&nbsp;
Initially hopeful, Alzheimer&#8217;s experts anticipated challenges with Leqembi&#8217;s requirements, including frequent infusions and diagnostic tests, leading to slow adoption&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33148410/expanded-medicare-coverage-for-biogen-eisais-leqembi-signals-a-turning-point-in-alz" rel="noreferrer noopener">after FDA approval</a>.&nbsp;
Interviews with 20 neurologists and geriatricians revealed concerns about efficacy, costs, and risks, hampering widespread prescription.
Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37897025/european-medicines-agency-delays-approval-decision-for-biogen-eisai-partnered-alzheimers-drug-lec" rel="noreferrer noopener">European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer&#8217;s Drug Lecanemab</a>.
Reuters highlighted that seven interviewed doctors cited skepticism, while six highlighted &#8220;therapeutic nihilism&#8221; as a significant barrier to Leqembi adoption.&nbsp;
Dr. Reisa Sperling likened skepticism to past fatalistic attitudes toward cancer treatment. Eisai&#8217;s chief administrative officer,&nbsp;Alex Scott, acknowledged skepticism&#8217;s impact, citing historical skepticism toward Alzheimer&#8217;s research.
In trials, Leqembi,&nbsp;targeting&nbsp;amyloid, showed a 27%&nbsp;cognition decline slowdown.&nbsp;However, adoption has been sluggish, with only a fraction of intended patients receiving treatment.&nbsp;
Factors include long adoption cycles for new drugs and concerns about Leqembi&#8217;s efficacy and costs.
Despite FDA approval, less than half of U.S. neurologists recommend Leqembi, citing limited patient benefit and significant risks.&nbsp;
Dr. Michael Greicius doubts Leqembi&#8217;s meaningful patient benefits, given slim trial differences, Reuter writes.&nbsp;Dr. Eric Widera and Donna Fick caution about the drug&#8217;s risks and unclear benefits.
Some physicians have expressed worries regarding the potential for brain swelling and bleeding linked to Leqembi.&nbsp;
They&#8217;ve also highlighted concerns about the financial burden imposed by the drug&#8217;s&nbsp;$26,500&nbsp;yearly cost, along with the expenses related to regular MRIs and bi-monthly infusions.
Reuters notes that of the 10,000 Americans the companies hoped to treat by the end of March, Eisai announced that only a couple thousand had begun treatment as of January.&nbsp;
Biogen and Eisai intend to increase their sales force by 30%, aiming for 100,000 patients by 2026.
In its first-quarter earnings release, Biogen said Leqembi launch uptake accelerated with first-quarter global in-market sales of approximately&nbsp;$19 million, nearly triple the fourth quarter of 2023, and patients on therapy increasing&nbsp;nearly&nbsp;2.5 times&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38410191/biogens-leqembi-commercial-ramp-up-modest-but-up-ticking-reports-mixed-bag-q1-earnings" rel="noreferrer noopener">since the end of 2023</a>.&nbsp;
Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36871446/biogen-gives-up-on-aduhelm-efforts-after-two-years-of-controversial-fda-accelerated-approval-for-" rel="noreferrer noopener">Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer&#8217;s, Shifts Focus On Newer Medicines</a>.
Price Action:&nbsp;BIIB shares are up 3.36% at $199.68&nbsp;at the last check Wednesday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo by Gerd Altmann via Pixabay

Large Cap

BIIB

ESALY

Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why

InflaRx reports FY results

Inflarx N.V. (IFRX) has released an update. InflaRx N.V., a biotech firm targeting anti-inflammatory therapeutics, announced plans to focus on immu...

InflaRx N.V. Targets Immuno-Dermatology Growth

BILI, EXAI and ENVB among pre-market losers

reported that it broke-even during the quarter.   The stock is down 7.10% to $1.57 after the report.The firm's lower revenue growth to earnings signals that the firm has been able to reduce costs and improve its profit margin overall.The average recommendation from Wall Street analysts was a Strong Buy which may get revis

Fireman B.V. Down 7.10% To $1.57 After Earnings

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
InflaRx (NASDAQ:<a href="https://investorplace.com/stock-quotes/ifrx-stock-quote/">IFRX</a>) just reported results for the fourth quarter of 2023.<ul><li>InflaRx reported earnings per share of -30 cents. This was below the analyst estimate for EPS of -20 cents.</li><li>The company reported revenue of $2,461.</li><li>This was 99.82% worse than the analyst estimate for revenue of $1.40 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/ifrx-stock-earnings-inflarx-for-q4-of-2023/">IFRX Stock Earnings: InflaRx Misses EPS, Misses Revenue for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

IFRX Stock Earnings: InflaRx Misses EPS, Misses Revenue for Q4 2023

Inflarx N.V. (IFRX) has released an update. InflaRx N.V., a biotech company specializing in anti-inflammatory therapeutics, has emphasized its comm...

InflaRx Advances Anti-Inflammatory Therapeutics

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on InflaRx (IFRX – Research Report), with a price target of $...

Buy Rating Justified for InflaRx Despite Earnings Miss: Financial Stability and INF904's Market Potential

In a report released today, Sam Slutsky from LifeSci Capital maintained a Hold rating on InflaRx (IFRX – Research Report). The company's shares ope...

LifeSci Capital Reaffirms Their Hold Rating on InflaRx (IFRX)

Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on InflaRx (IFRX – Research Report) on March 21 and set a price target of $5.00. J...

Investor Optimism for InflaRx's INF904: Assessing Potential in CSU and HS Markets

Inflarx N.V. (IFRX) has released an update. InflaRx N.V. has announced its annual general meeting (AGM) to be held in Amsterdam on April 25, 2024, ...

InflaRx N.V. Announces 2024 AGM Details

ANGH

APYX

BILI

BZUN

DNMR

DXLG

ENVB

EXAI

FIVE

PALT

PYXS

TRML

TRUG

WORX

Press Releases

InflaRx's Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)

InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update

InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904

InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients

Management

InflaRx Appoints Jan Medina as Head of Investor Relations

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans

InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event

HC Wainwright & Co.